N
News Analysis
tickerreport.com

www.tickerreport.com ·

Positive

entrada therapeutics nasdaqtrda trading up 7 6 still a buy

GENERAL_HEALTHTAX_DISEASE_DISEASESUNGP_HEALTHCAREDRUG_TRADE

All NewsRead the full story on tickerreport.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

The article reports a single-day stock price increase for Entrada Therapeutics (TRDA) with low volume and weak fundamentals (revenue miss, insider selling). No concrete commercial mechanism (product pipeline, regulatory event, partnership) is mentioned. The price move appears speculative or noise-driven; no clear impact on revenue, margin, or supply chain.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • TRDA stock rose 7.6% on May 6, 2026, closing at $15.6010.
  • Volume was 41,940 shares vs. average 211,064 shares.
  • Company reported quarterly loss of $0.94 per share on revenue of $1.30M, below consensus $7.41M.
  • Analyst average target price is $19.00, with mixed ratings.
  • Insiders sold shares: Natarajan Sethuraman (25,907 shares) and CFO Kory James Wentworth (2,500 shares).
entrada therapeutics nasdaqtrda trading up 7 6 still a buy | tickerreport.com — News Analysis